Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: New anticoagulants, new hope

European Heart Journal

Volumn 32, Issue 19, 2011, Pages 2347-2349

  Hohnloser, Stefan H ^a   Connolly, Stuart J ^b  

^a GOETHE UNIVERSITY   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN;

CHRONIC KIDNEY DISEASE; DATA BASE; EMBOLISM; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; NOTE; PRIORITY JOURNAL; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY; STROKE;

EID: 80054074793     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr344     Document Type: Note

References (15)

1. Coresh J, Selvin E, Stevens LA. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047. (Pubitemid 350074801)
2. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, mohler ER, Wright JT, Feldman HI. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102-1107.
3. Alonso A, Lopez FL, Matsishita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation. The Artherosclerosis risk in communities (ARIC) study. Circulation 2011;123:2946-2953.
4. Seliger SL, Gillen DL, Logstreth WT Jr, Kestenbaum B, Steman-Breen CO. Elevated risk of stroke among patients with endstage renal disease. Kidney Int 2003;64: 603-609. (Pubitemid 36871932)
5. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE, for the ATRIA study investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. Circulation 2009;119: 1363-1369.
6. Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009;54:1280-1289.
7. Reinecke H, Brand E, Mesters R, Schaebitz WR, Fisher M, Pavenstädt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705-711.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
9. Connolly S, Eikelboom J, Joyner C, Diener H, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan R, Sim K, Lewis B, Van Mieghem W, Lip G, Kim J, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans A, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; in press.
11. Kubitza D, Becka M,Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61: 873-880. (Pubitemid 41803696)
12. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-2765.
13. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703-712.
14. Fox KAA, Piccini JP, Wojdyla D, Becker CR, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394. First published on 28 August 2011. doi:10.1093/eurheartj/ehr342.
15. Eikelboom J, Wallentin L, Connolly S, Ezekowitz M, Healey J, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener H, Franzosi M, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation 2011; 123:2363-2372.